Sickle Cell Disease Critique Template

Sickle Cell Disease Critique Template

Not all-inclusive – if you have another idea, but aren’t sure if it fits under the biotech umbrella, please email me or stop by with a copy of the article. Remember, if it is not on this list, it must be pre-approved.
Articles used for journal critiques must be research articles (clinical trial, case reports or meta-analyses), not review or continuing education articles.

Note that these topics would also apply for the popular media critiques, and many of the general topics would be good ideas for the fictional critiques (i.e. books/movies such as “Boys from Brazil” and “Jurassic Park” deal with cloning, “Gattaca” deals with genetic engineering and testing).

General topics:

• Biosimilars
• Stem cell research
• Cloning
• Genetically modified food or animals / Biopharming
• Polymerase chain reaction
• Blotting techniques (southern, northern, western)
• Pharmacogenomics
• Biotech techniques as used in forensics / DNA profiling
• Genome editing
• Gene therapy
• RNA interference / RNAi
• Antisense / morpholinos
• CAR-T
• Genetic testing
• Neutralizing antibodies as potential Covid treatment; testing methods for such antibodies

Hematopoietic growth factors

• Filgrastim (Neopogen®, Zarxio®)
• Pegfilgrastim (Neulasta®)
• Tbo-filgrastim (Granix®)
• Sargramostim (Leukine®)
• Erythropoietin (Epogen®, Procit®)
• Darbapoetin (Aranesp®)

Cytokines and Antagonists
• Interleukins
 Interleukin-2 (Proleukin®)
 Interleukin-11 (Neumega®)
 Denileukin Difitox (Ontak®)

• Interferons
 Interferon alpha-2a (Roferon®, Pegasys®)
 Interferon alpha-2b (Intron A®, Rebetron®, PEG-Intron®)
 Interferon alfacon-1 (Infergen®)
 Interferon alfa-N3 (Alferon N®)
 Interferon beta-1a (Rebif®, Avonex®)
 Interferon beta-1b (Betaseron®, Extavia®)
 Interferon gamma-2b (Actimmune®)
 Interferon lambda (in development)

• Interleukin / TNF antagonists

 Anakinra (Kineret®)

Becaplermin (Regranex®)

Hormones (derived from biotechnology sources only)
• Glucagon (GlucaGen®, Baqsimi®, Gvoke®)
• Inhaled insulin (Afrezza®)
• Buccal insulin (Oral-lyn®)
• Growth hormone
 Somatrem (Protropin®)
 Somatropin (Humatrope®, Nutropin®, Saizen®, Serostim®)
• Follicle-stimulating hormone
 Follitropin alpha (Gonal-F®)
 Follitropin beta (Follistim®)

Enzymes (Partial list. Only recombinant enzymes are acceptable)
• Alteplase (Activase®)
• Asfotase alfa (Strensig®)
• Avalglucosidase alfa-ngpt (Nexviazyme®)
• C1 esterase inhibitor (Ruconest®)
• Cerliponase alfa (Brineura®)
• Dornase alpha (Pulmozyme®)
• Drotrecogin alpha (Xigris®) – no longer on market
• Elosulfase alfa (Vimizim®)
• Imiglucerase (Cerezyme®)
• Pegaspargase (Oncaspar®)
• Pegloticase (Krystexxa®)
• Pegvaliase-pjpz (Palynziq™)
• Retaplase (Retevase®)
• Sebelipase alfa (Kanuma®)
• Tenecteplase (TNKase®)

Coagulation and anti-coagulation factors
• Antihemophilic Factor / von Willebrand Factor complex (Humate-P®)
• Antihemophilic Factor (recombinant) Fc Fusion Protein1 (Eloctate™)
• Bivalirudin (Angiomax®)
• Desirudin (Ipravask®)
• Eptifibatide (Integrilin®)
• Factor VIIa (NovoSeven®)
• Factor VIII (Advate®, Eloctate®, Helixate®, Kogenate FS®, Novoeight®, Recombinate®, Xyntha®, Nuwiq®)
• Factor IX (Alprolix®, Rixubis®, Benefix®, Ixinity®)
• Lepirudin (Refludan®)
• von Willebrand Factor (Vonvendi®)

Sickle Cell Disease Critique Template

Monoclonal antibodies and fusion proteins (may include others in development; biosimilar names not included here)

• Abatacept (Orencia®)
• Abciximab (Reopro®)
• Adalimumab (Humira®)
• Ado-trastuzumab emtansine (Kadcyla®)
• Aducanumab (in development)
• Aflibercept (Eylea®)
• Alemtuzumab (Campath-1H®, Lemtrada®)
• Alirocumab (Praluent®)
• Amatuximab – in development
• Amivantamab-vmjw (Rybrevant®)
• Anifrolumab (Saphnelo®)
• Atezolizumab (Tecentriq®)
• Avelumab (Bavencio®)
• Basiliximab (Simulect®)
• Belatacept (Nulojix®)
• Belimumab (Benlysta®)
• Benralizumab (Fasenra®)
• Bevacizumab (Avastin®)
• Bezlotoxumab (Zinplava®)
• Blinitumomab (Blincyto®)
• Brentuximab vedotin (Adcetris®)
• Brodalumab (Siliq®)
• Burosumab-twza (Crysvita®)
• Canakinumab (Ilaris®)
• Caplacizumab-yhdp (Cablivi®)
• Cemiplimab-rwlc (Libtayo®)
• Certolizumab (Cimizia®)
• Cetuximab (Erbitux®)Crizanlizumab-tmca (Adakveo®)
• Daclizumab (Zenapax®, Zinbryta®)
• Daratumumab (Darzalex®)
• Denosumab (Prolia®, Xgeva®)
• Dinutuxumab (Unituxin®)
• Dostarlimab (Jemperli®)
• Dupilumab (Dupixent®)
• Eculizumab (Soliris®)
• Elotuzumab (Empliciti®)
• Emapalumab-lzsg (Gamifant®)
• Emicizumab-kxwh (Hemlibra®)
• Epratuzumab – in development
• Erenumab-aooe (Aimovig®)
• Eternacept (Enbrel®)
• Evolocumab (Repatha®)
• Fremanezumab-vfrm (Ajovy®)
• Galcanezumab-gnlm (Emgality®)
• Golimumab (Simponi®)
• Guselkumab (Tremfya®)
• Ibalizumab-uiyk (Trogarzo®)
• Ibritumomab tiuxetan (Zevulin Y-90®)
• Idarucizumab (Praxbind®)
• Infliximab (Remicade®)
• Inotuzumab ozogamicin (Besponsa®)
• Ipilumomab (Yervoy®)
• Ixekizumab (Taltz®)
• Lanadelumab-flyo (Takhzyro®)
• Luspatercept-aamt (Reblozyl®)
• Mepolizumab (Nucala®)
• Mogamulizumab-kpkc (Poteligeo®)
• Moxetumomab pasudotox-tdfk (Lumoxiti®)
• Natalizumab (Tysabri®)
• Necitumumab (Portrazza®)
• Nivolumab (Opdivo®)
• Obiltoxaximab (Anthim®)
• Obinutuzumab (Gazyva®)
• Ocrelizumab (Ocrevus®)
• Ofatumumab (Arzerra®)
• Olaratumab (Lartruvo®)
• Omalizumab (Xolair®)
• Palivizumab (Synagis®)
• Panitumumab (Vectibix®)
• Pembrolizumab (Keytruda®)
• Pertuzumab (Perjeta®)
• Polatuzumab vedotin-piiq (Polivy®)
• Ramucirumab (Cyramza®)
• Ranibizumab (Lucentis®, Susvimo®)
• Ravulizumab-cwvz (Ultomiris®)
• Raxibacumab
• Reslizumab (Cinqair®)
• Rilonacept (Arcalyst®)
• Risankizumab-rzaa (Skyrizi®)
• Rituximab (Rituxan®)
• Romosozumab-aqqg (Evenity®)
• Sarilumab (Kevzara®)
• Secukinumab (Cosentyx®)
• Siltuximab (Sylvant®)
• Tildrakizumab-asmn (Ilumya®)
• Tocilizumab (Actevma®)
• Trastuzumab (Herceptin®)
• Ustekinumab (Stelara®)
• Vedolizumab (Entyvio®)
• Ziv-aflibercept (Zaltrap®)
• Zmapp (trio of monoclonals for ebola) – in development

Antisense oligonucleotides (topic in general, or one of products below):

• Affinitak
• Alicaforsen (Camligo®)
• Eteplirsen (Exondys 51)
• Fomiversen (Vitravene®)
• Mipomersen (Kynamro®)
• Nusinersen (Spinraza®)
• Oblimersen (Genasense®)

RNA interference (topic in general, or product below):
• Patisiran (Onpattro®)

Gene therapies (topic in general, or one of products below):
• Axicabtagene ciloleucel (Yescarta®)
• Talimogene laherparepvec (Imlygic®)
• Voretigene neparvovec-rzyl (Luxturna®)

Other products produced by genetic engineering, recombinant or gene-editing methods
• Sipuleucel-T (Provenge®) – recombinant cancer vaccine
• Tisagenlecleucel (Kymriah®)